Photo from Stephen V Liu/X
Jan 16, 2024, 05:48
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:
“Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines including:
– amivantamab + carbo/pem preferred 1L for EGFR exon 20 (PAPILLON)
– amivantamab + carbo/pem for EGFR post osimertinib (MARIPOSA2)
– repotrectinib for 1L ROS1 (TRIDENT)
– atezolizumab monotherapy for PS3 (IPSOS).”
Source: Stephen V Liu/X